P&T Community |

LATEST NEWS

New gene therapies, deeper insights into stem cells, and advances in imaging and artificial intelligence are making researchers, physicians, and some patients optimistic about retinal disease treatment.

Talicia Approved for Treatment of H. Pylori in Adults

New drug addresses bacterial resistance to standard therapy

In a First, UPS Drones Deliver Prescriptions to CVS Customers

Hovering flights lower packages by cable and winch

FDA Approves a Sandoz Biosimilar for Neulasta

Ziextenzo helps lower the incidence of febrile neutropenia

Her Genes Cause Early Alzheimer’s—So How Did She Avoid It?

The answer may offer a potential treatment for the disease

FDA Authorizes New Type of Test to Find Drug-Resistant HIV

Drug resistance in HIV patients has nearly tripled since 2001

FDA Authorizes New Type of Test for Drug-Resistant HIV

Drug resistance in HIV patients has nearly tripled since 2001

Prime Therapeutics Says 'Super Spender' Numbers Are Growing

The number of those with an annual drug spend of $250K or more has increased by 60%

Drug Shortage Report Recommends a Rating System for Manufacturers

Grading manufacturers would give high-quality, reliable makers a boost, says federal panel

MD Anderson's Hahn Tapped for FDA Commissioner Post

Sharpless is heading back to NCI

FDA Recommends Boxed Warnings for Breast Implants

Agency guidance seeks to inform women about implant risks

P&T October 2019
Table of Contents

Features

The Future of Retinal Disease Treatment

Stem Cell Research, Gene Therapies, and Sophisticated Retinal Imaging Techniques

New gene therapies, deeper insights into stem cells, and advances in imaging and artificial intelligence are making researchers, physicians, and some patients optimistic about retinal disease treatment.

The Safety of Direct Oral Anticoagulants with P2Y12 Inhibitors: A Systematic Review and Meta-Analysis of Clinical Trials

Meta-analysis shows that DOACs with P2Y12 inhibitors were associated with lower bleeding rates than warfarin with triple antithrombotic therapy.

The Hidden Inactive Ingredient: Biological Products in Recombinant Pharmaceuticals

This review describes the inactive ingredients in recombinant pharmaceuticals and how they relate to dietary prohibitions for faith and other reasons.

Meeting Highlights

Heart Failure Society of America 2019

Summaries of selected sessions from HFSA 2019: clinical effectiveness of sacubitril/valsartan; use of low-dose dopamine; the cost effectiveness of routine surveillance for organ rejection after heart transplant; inotrope therapy survival rates; and adherence rates of patients with multiple prescriptions.